ST吉药(300108) - 2015 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2015 reached ¥164,619,738.85, a significant increase of 302.15% compared to ¥40,934,455.24 in the same period last year[9] - Net profit attributable to shareholders was ¥34,361,722.62, reflecting a remarkable growth of 470.31% from ¥6,025,053.87 year-on-year[9] - Basic earnings per share increased by 171.11% to ¥0.122 from ¥0.045 in the previous year[9] - The company reported a net profit increase, with retained earnings growing to ¥177,534,078.13 from ¥144,989,344.17, a rise of approximately 22.4%[43] - Net profit for the current period reached ¥35,023,902.97, compared to ¥6,025,053.87 in the previous period, marking an increase of around 481.5%[50] Cash Flow - The net cash flow from operating activities was negative at -¥76,527,815.27, worsening by 198.90% compared to -¥25,603,240.08 in the same period last year[9] - Cash inflow from operating activities totaled ¥97,661,659.19, a substantial rise from ¥29,386,412.74 in the prior period, representing an increase of about 231.5%[58] - The net cash flow from operating activities was -76,527,815.27, compared to -25,603,240.08 in the previous period, indicating a decline in operational performance[60] - The total cash outflow from operating activities was 174,189,474.46, compared to 54,989,652.82 in the previous period, highlighting increased operational costs[60] - The cash flow from operating activities net amount of -4,824,095.77, an improvement from -26,996,906.67 in the previous period, reflecting better operational efficiency[64] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,206,102,176.97, up 1.76% from ¥2,167,906,367.04 at the end of the previous year[9] - Total current assets increased to ¥951,368,465.46 from ¥896,455,998.22, representing a growth of approximately 6.5%[39] - Total liabilities increased to ¥652,865,732.27 from ¥647,876,836.65, reflecting a growth of about 0.3%[41] - Non-current assets decreased to ¥1,254,733,711.51 from ¥1,271,450,368.82, a decline of about 1.3%[40] Shareholder Information - The total number of shareholders at the end of the reporting period was 6,679, with the largest shareholder holding 24.86% of the shares[15] - The company has not violated any commitments regarding share transfers or management of shares by major shareholders since the stock market listing[30] - The company has revised its profit distribution policy to enhance cash dividend systems and protect investors' rights[33] - The company has established a dividend management system to further clarify and refine its profit distribution policy[33] Business Strategy and Outlook - The company anticipates improved sales in the next quarter due to the launch of two fundraising projects, although increased depreciation and labor costs may impact profits[13] - The acquisition of Jinbao Pharmaceutical has expanded the company's asset scale and business scope, necessitating integration efforts to avoid operational challenges[13] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[42] - The company is in the research phase for several new products, including various types of precipitated silica for different applications[23][25] Financial Expenses - The company reported a significant increase in financial expenses, which rose by 694.73% to ¥6,002,430.44 from ¥755,276.26[22] - The company's management expenses increased to ¥11,165,158.22 from ¥4,986,193.79, representing a growth of approximately 124.0%[50]